{"doi":"10.2147/idr.s8673","title":"Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy","abstract":null,"journal":"Infection and Drug Resistance","year":2010,"id":604970,"datarank":0.16409198560194627,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.06011990851795444,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.06011990851795444,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":1,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":69656,"name":"Charlotte Charpentier","orcid":"0000-0002-6441-7054","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy","abstract":"Raltegravir is the first licensed compound in 2007 of the new integrase inhibitor drug class. At the dose of 400 mg twice daily, raltegravir showed a potent antiviral action in antiretroviral-naïve patients when associated with tenofovir and emtricitabine. Raltegravir was also found to be highly active in antiretroviral-experienced patients with virological failure and displaying multiresistant virus, as shown with the BENCHMRK and ANRS 139 TRIO trials. Finally, the use of raltegravir was assessed in the context of a switch strategy in antiretroviral-experienced patients with virological success [human immunodeficiency virus type 1 (HIV-1) RNA below detection limit], highlighting the following mandatory criteria in this strategy: the nucleoside reverse transcriptase inhibitors associated with raltegravir have to be fully active. In the different studies, raltegravir had a favorable safety and tolerability profile. In the clinical situation a switch in virologically suppressed patients receiving a protease inhibitor, an improvement of the lipid profile was observed. Overall, when analyzing the Phase II and III trials together, only a few patients on raltegravir discontinued for adverse events. The development of resistance to raltegravir mainly involved three resistance mutations in integrase gene: Q148H/K/R, N155H, and Y143C/H/R. In conclusion, raltegravir improved the clinical management of HIV-1 infection both in antiretroviral-naïve and in antiretroviral-experienced patients.","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21694899","pmcid":"PMC3108740","openalex_id":"https://openalex.org/W2006715152","authors":[],"funders":[],"total_grants":0,"fwci":0.148,"citation_percentile":0.49288292,"influential_citations":0,"citation_trend":[{"year":2013,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.dovepress.com/getfile.php?fileID=7929","host_type":"journal"},{"url":"https://www.dovepress.com/getfile.php?fileID=7929","host_type":"publisher"},{"url":"https://doi.org/10.2147/idr.s8673","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21694899","host_type":"repository"},{"url":"https://doaj.org/article/4d83c56eba3c42aabf4d11a8c27ab7d1","host_type":"repository"},{"url":"https://www.dovepress.com/extended-use-of-raltegravir-in-the-treatment-of-hiv-1-infection-optimi-peer-reviewed-article-IDR","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3108740","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC3108740","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC3108740?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["HIV/AIDS drug development and treatment","HIV Research and Treatment","Biochemical and Molecular Research"],"mesh_terms":[],"keywords":["Raltegravir","Integrase inhibitor","Integrase","Tolerability","Virology","Elvitegravir","Medicine","Context (archaeology)","Adverse effect","Pharmacology","Clinical trial","Human immunodeficiency virus (HIV)","Viral load","Internal medicine","Biology","Antiretroviral therapy","HIV-1","Integrase Inhibitors"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T01:18:45.205755Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}